Fig. 8From: FNDC5/irisin improves the therapeutic efficacy of bone marrow-derived mesenchymal stem cells for myocardial infarctionProposed hypothesis of FNDC5/irisin improving the therapeutic efficacy of BM-MSCs for MI. FNDC5/irisin may protect against promoted apoptosis and paracrine dysfunction of BM-MSCs induced by hypoxia. Furthermore, FNDC5/irisin may contribute to enhance the low survival of engrafted BM-MSCs and ameliorate cardiac dysfunction after MIBack to article page